Kuros Biosciences

Historical price data

Kuros Biosciences is a commercial-stage orthobiologics company with a mission to address unmet clinical needs for safer, faster, and more predictable bone healing. Its core technology, MagnetOs, is supported by a robust clinical evidence program called Project Fusion, which includes Level I human clinical data demonstrating superior fusion rates compared to autograft. The company leverages a global commercial footprint and strategic advisory boards of leading surgeons to drive adoption of its products in spinal fusion and other orthopedic procedures.

MagnetOs bone graft platform featuring proprietary NeedleGrip surface technology, a biphasic calcium phosphate ceramic with a needle-shaped submicron topography designed to harness osteoimmunology and stimulate predictable, vascularized bone growth.

Total raised: $52.5M

Kuros competes in the crowded bone graft substitute market against giants like Medtronic, Stryker, and Zimmer Biomet. Its main differentiation is the proprietary NeedleGrip surface technology combined with a strong focus on generating high-level (Level I) clinical evidence through its Project Fusion program, aiming to offer more predictable outcomes than many synthetic alternatives.